Protocol Ledger

NCT06477237 · Phase III · COMPLETED

Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Interventional Phase III clinical trial protocol NCT06477237 sponsored by Huabo Biopharm Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-29 Enrollment: 408 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06477237
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)408 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06477237
Protocol FieldVerified Registry Value
NCT IdentifierNCT06477237
Consolidated Lead SponsorHuabo Biopharm Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment408 participants (ACTUAL)
Registered Start Date2024-03-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI